United Therapeutics Corp
UTHR309.220USD
0.0000.00%
Handelsschluss 08/26, 16:00（ET）Kurse um 15 Minuten verzögert
13.98BMarktkapitalisierung
11.55KGV TTM
mehr Informationen über United Therapeutics Corp Unternehmen
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Unternehmensinformationen
BörsenkürzelUTHR
Name des UnternehmensUnited Therapeutics Corp
IPO-datumJun 17, 1999
CEODr. Martine A. Rothblatt
Anzahl der mitarbeiter1305
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
Addresse1000 Spring St
StadtSILVER SPRING
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl20910
Telefon13016089292
Websitehttps://www.unither.com/
BörsenkürzelUTHR
IPO-datumJun 17, 1999
CEODr. Martine A. Rothblatt
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
-0.06%
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
+29.50%
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
1.22K
+93.65%
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
-0.06%
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
749.60M
94.36%
Rest of World
44.80M
5.64%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Andere
65.89%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Andere
65.89%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.79%
Investment Advisor/Hedge Fund
37.76%
Hedge Fund
9.20%
Pension Fund
4.79%
Individual Investor
1.76%
Research Firm
1.73%
Bank and Trust
1.43%
Sovereign Wealth Fund
1.24%
Venture Capital
0.46%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
2023Q2
1068
46.82M
99.96%
-3.45M
2023Q1
1055
47.11M
101.08%
-1.09M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
4.44M
9.84%
+15.26K
+0.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.48M
9.93%
+12.87K
+0.29%
Mar 31, 2025
Avoro Capital Advisors LLC
2.67M
5.93%
-85.30K
-3.09%
Mar 31, 2025
State Street Global Advisors (US)
2.23M
4.95%
+30.71K
+1.40%
Mar 31, 2025
Renaissance Technologies LLC
2.11M
4.67%
+17.60K
+0.84%
Mar 31, 2025
Wellington Management Company, LLP
2.03M
4.49%
-437.48K
-17.76%
Mar 31, 2025
AQR Capital Management, LLC
908.45K
2.01%
-67.00K
-6.87%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.22M
2.71%
+85.70K
+7.53%
Mar 31, 2025
LSV Asset Management
902.32K
2%
-6.40K
-0.70%
Mar 31, 2025
Invesco Capital Management LLC
376.17K
0.83%
+246.08K
+189.17%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco Biotechnology & Genome ETF
4.45%
First Trust NASDAQ Pharmaceuticals ETF
3.62%
Formidable Fortress ETF
3.24%
First Trust NYSE Arca Biotechnology Index Fund
3.21%
Franklin Genomic Advancements ETF
3%
SPDR S&P Biotech ETF
2.53%
Inspire Faithward Mid Cap Momentum ETF
2.48%
Invesco Pharmaceuticals ETF
2.47%
Invesco S&P MidCap Quality ETF
2.41%
Alger Russell Innovation ETF
2.09%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil4.45%
First Trust NASDAQ Pharmaceuticals ETF
Anteil3.62%
Formidable Fortress ETF
Anteil3.24%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.21%
Franklin Genomic Advancements ETF
Anteil3%
SPDR S&P Biotech ETF
Anteil2.53%
Inspire Faithward Mid Cap Momentum ETF
Anteil2.48%
Invesco Pharmaceuticals ETF
Anteil2.47%
Invesco S&P MidCap Quality ETF
Anteil2.41%
Alger Russell Innovation ETF
Anteil2.09%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
